Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
12 04 2022
Historique:
received: 05 08 2021
accepted: 07 12 2021
pubmed: 12 1 2022
medline: 14 4 2022
entrez: 11 1 2022
Statut: ppublish

Résumé

Mature T-cell lymphomas (TCLs) are rare, clinically heterogeneous hematologic cancers with high medical need. TCLs have an inferior prognosis which is attributed to poor understanding of their pathogenesis. On the basis of phenotypic similarities between normal and neoplastic lymphocytes, it has been assumed that TCLs develop in the periphery, directly from various subtypes of normal T cells. To address the debated question of the cell of origin in TCLs, we attempted to identify the highly variable complementarity-determining regions (CDRs) of T-cell receptors (TCRs) to trace the clonal history of the T cells. We have collected previously published whole-genome, whole-exome, and whole-transcriptome sequencing data from 574 patients with TCL. TCR clonotypes were identified by de novo assembly of CDR3 regions of TCRα, TCRβ, and TCRγ. We have found that the vast majority of TCLs are clonotypically oligoclonal, although the pattern of oligoclonality varied. Anaplastic large-cell lymphoma was the most diverse comprising multiple clonotypes of TCRα, TCRβ, and TCRγ, whereas adult TCL or leukemia and peripheral TCLs often showed monoclonality for TCRβ and TCRγ but had diverse TCRα clonotypes. These patterns of rearrangements indicated that TCLs are initiated at the level of the lymphoid precursor. In keeping with this hypothesis, TCR rearrangements in TCLs resembled the pattern seen in the human thymus, which showed biased usage of V (variable) and J (joining) segments of high combinatorial probability resulting in recurrent public CDR3 sequences shared across unrelated patients and different clinical TCL entities. Clonotypically diverse initiating cells may seed target tissues that are then responsible for disease relapses after therapy.

Identifiants

pubmed: 35015812
pii: 483431
doi: 10.1182/bloodadvances.2021005884
pmc: PMC9006294
doi:

Substances chimiques

Receptors, Antigen, T-Cell, gamma-delta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2334-2345

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Nat Genet. 2015 Sep;47(9):1061-6
pubmed: 26192917
Bioinformatics. 2019 Sep 1;35(17):2974-2981
pubmed: 30657870
PLoS One. 2015 Nov 04;10(11):e0141906
pubmed: 26536348
J Clin Invest. 1989 Apr;83(4):1277-83
pubmed: 2522937
Genome Res. 2009 Oct;19(10):1817-24
pubmed: 19541912
Nat Genet. 2015 Dec;47(12):1465-70
pubmed: 26551667
Sci Rep. 2017 Dec 21;7(1):17977
pubmed: 29269859
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12323-E12332
pubmed: 30541895
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13139-44
pubmed: 25157137
Exp Dermatol. 2017 May;26(5):454-456
pubmed: 27714856
Blood. 2019 Oct 31;134(18):1517-1527
pubmed: 31515249
Immunology. 2020 Dec;161(4):354-363
pubmed: 32875554
Nat Genet. 2014 Apr;46(4):371-5
pubmed: 24584070
Nature. 1988 Aug 4;334(6181):395-402
pubmed: 3043226
J Clin Invest. 2012 Apr;122(4):1403-15
pubmed: 22378041
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18691-6
pubmed: 17130450
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Nat Struct Mol Biol. 2014 May;21(5):480-8
pubmed: 24777060
Sci Adv. 2021 May 14;7(20):
pubmed: 33990328
Genome Res. 2014 Nov;24(11):1881-93
pubmed: 25060187
Nat Rev Cancer. 2020 Jun;20(6):323-342
pubmed: 32249838
Nat Genet. 2016 Mar;48(3):238-244
pubmed: 26780609
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18172-18174
pubmed: 32690689
J Clin Invest. 2020 Dec 1;130(12):6395-6408
pubmed: 33141118
PLoS Pathog. 2010 Nov 18;6(11):e1001198
pubmed: 21124993
Leukemia. 2012 Oct;26(10):2159-71
pubmed: 22918122
Nat Commun. 2018 Feb 8;9(1):561
pubmed: 29422654
J Immunol. 2018 Dec 1;201(11):3465-3470
pubmed: 30381480
Oncogene. 2015 Apr 2;34(14):1843-52
pubmed: 24814516
J Clin Invest. 2012 Dec;122(12):4716-26
pubmed: 23160195
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
J Invest Dermatol. 1992 Jan;98(1):33-7
pubmed: 1728639
Nature. 2021 May;593(7860):522-527
pubmed: 34040209
J Crohns Colitis. 2020 Jul 9;14(6):778-790
pubmed: 31711184
Br J Haematol. 2018 May;181(3):406-410
pubmed: 28294301
Nat Genet. 2015 Dec;47(12):1426-34
pubmed: 26551670
Blood Adv. 2020 Jun 9;4(11):2489-2500
pubmed: 32502269
Science. 2020 Feb 21;367(6480):
pubmed: 32079746
J R Soc Interface. 2018 Dec 21;15(149):20180395
pubmed: 30958235
Adv Exp Med Biol. 2009;650:116-32
pubmed: 19731806
Blood. 2003 Nov 15;102(10):3797-9
pubmed: 12842987
Nat Genet. 2015 Sep;47(9):1011-9
pubmed: 26192916
Sci Transl Med. 2018 May 9;10(440):
pubmed: 29743350
Oncoimmunology. 2016 Jun 06;5(7):e1175799
pubmed: 27622024
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood Adv. 2019 Apr 9;3(7):1175-1184
pubmed: 30967393
Expert Rev Hematol. 2017 Mar;10(3):239-249
pubmed: 28133975
Leukemia. 2004 Apr;18(4):709-19
pubmed: 14961040
J Immunol. 2005 Oct 1;175(7):4363-73
pubmed: 16177077
Science. 1999 Oct 29;286(5441):958-61
pubmed: 10542151
Genome Res. 2011 May;21(5):790-7
pubmed: 21349924
Cell. 2004 Sep 3;118(5):539-44
pubmed: 15339659
Sci Transl Med. 2015 Oct 7;7(308):308ra158
pubmed: 26446955
Br J Haematol. 2020 Apr;189(1):54-66
pubmed: 32064593
Nat Genet. 2014 Jul;46(7):736-41
pubmed: 24880342
CA Cancer J Clin. 2020 Jan;70(1):47-70
pubmed: 31815293
Blood. 1993 Jul 1;82(1):207-16
pubmed: 8391873
Nat Genet. 2015 Sep;47(9):1056-60
pubmed: 26258847
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Nat Rev Immunol. 2006 Dec;6(12):883-94
pubmed: 17110956
Cancer Cell. 2015 Apr 13;27(4):516-32
pubmed: 25873174
Blood. 2013 Dec 12;122(25):4077-85
pubmed: 24149287
Blood. 2015 Jul 23;126(4):508-19
pubmed: 26082451
Blood. 2003 Apr 1;101(7):2693-703
pubmed: 12446444
Mol Immunol. 2020 Nov;127:112-123
pubmed: 32961421
N Engl J Med. 2001 Nov 15;345(20):1458-63
pubmed: 11794194
Open Biol. 2016 Sep;6(9):
pubmed: 27683157
Nat Genet. 2016 Jul;48(7):725-32
pubmed: 27240091
J Invest Dermatol. 2006 Aug;126(8):1893-9
pubmed: 16741518

Auteurs

Aishwarya Iyer (A)

Division of Dermatology, Department of Medicine, and.

Dylan Hennessey (D)

Division of Dermatology, Department of Medicine, and.

Robert Gniadecki (R)

Division of Dermatology, Department of Medicine, and.
Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; and.
Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH